Markets:

Overview

News

Currencies

International

Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

8.790 +0.090 (+1.03%)

Streaming Delayed Price Updated: 11:39 AM EST, Feb 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗

Today 10:57 EST

Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.

Via The Motley Fool

Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗

Today 10:46 EST

Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.

Via The Motley Fool

Topics Regulatory Compliance

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗

Today 10:38 EST

Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Preview: Relay Therapeutics's Earnings ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗

Today 10:29 EST

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗

Today 10:21 EST

Nuvalent develops targeted cancer therapies, advancing clinical candidates for patients with limited treatment options in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run ↗

February 06, 2026

This clinical-stage biotech focused on precision oncology therapies reported an insider sale amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Why Relay Therapeutics (RLAY) Stock Is Down 17% Today ↗

September 11, 2024

Relay Therapeutics shares are trading lower by 17.8% during Wednesday's session. The company priced its $200 million offering.

Via Benzinga

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Relay Therapeutics Director Sells $300,000 Worth of Shares. Here's Why Investors Shouldn't Panic. ↗

December 03, 2025

Sometimes insiders sell shares because their conviction is changing. Sometimes it's just about bookkeeping.

Via The Motley Fool

Topics Regulatory Compliance

Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗

December 03, 2025

Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?

Via The Motley Fool

Topics Regulatory Compliance

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Topics Artificial Intelligence Economy Emissions

Relay Therapeutics Inc (NASDAQ:RLAY) Reports Q3 2025 Earnings Miss and Clinical Progress ↗

November 06, 2025

Relay Therapeutics reports Q3 2025 results, missing revenue estimates. The biotech firm maintains a strong cash position to fund its clinical trials for lead drug RLY-2608 into 2029.

Via Chartmill

Topics Earnings

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week ↗

September 05, 2025

The cancer-focused biotech has a bright future, according to one pundit.

Via The Motley Fool

Medtronic To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

August 26, 2025

Via Benzinga

Relay (RLAY) Q2 Loss Narrows 41% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

April 17, 2025

Via Benzinga

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

Why Relay Therapeutics Plummeted by Nearly 14% Today ↗

September 11, 2024

Investors weren't happy with the company's latest effort at capital-raising.

Via The Motley Fool

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

September 11, 2024

Via Benzinga

Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

September 11, 2024

Via Benzinga

Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market ↗

September 10, 2024

Relay Therapeutics shares interim data for RLY-2608 from the ReDiscover study, showing a 57% clinical benefit rate. Oppenheimer downgrades Relay Therapeutics from Outperform to Perform, citing concerns...

Via Benzinga

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗

September 10, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

September 10, 2024

Via Benzinga

Dow Jumps Over 1% Following Last Week's Selloff: Investor Sentiment Improves, But Fear & Greed Index Remains In 'Fear' Zone ↗

September 10, 2024

Via Benzinga

Topics Stocks

Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher ↗

September 09, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.